R1 RCM — FY2021 Earnings Presentation
15 slides from R1 RCM's earnings presentation, Feb 17, 2022
Slide 1: Fourth Quarter and Full Year 2021 Earnings Call
• January 10, 2022February 17, 2 22 Fourth Quarter and Full Year 2021 Earnings Call NEED NEW IMAGE THAT WE SENT Exhibit 99.2
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-lookin
Slide 3: Disclaimer: Additional Information and Where to Find It
3 Disclaimer Additional Information and Where to Find It In connection with the proposed transaction and plan of merger (the “Transaction Agreement”) by and among R1 RCM Inc. (“R1”), Project Roadrunner Parent Inc., a wholly owned subsidiary of R1 (“New Pubco”), Project Roadrunner Merger Sub Inc., a
Slide 4: Disclaimer: Financial Projections
4 Disclaimer Financial Projections All financial projections in this presentation are forward-looking statements that are based on assumptions that are inherently subject to significant uncertainties and contingencies, many of which are beyond R1’s control. No independent registered public accountin
Slide 5: Fourth Quarter and Full Year 2021 Financial Highlights
5 Fourth Quarter and Full Year 2021 Financial Highlights ▪ Revenue of $398.9 million, up $70.5 million or 21.5% compared to the same period last year ▪ GAAP net income of $36.0 million, down $42.6 million or 54.2% compared to the same period last year - 4Q’20 results included a $55.7 million gain on
Slide 6: 2021 Highlights
6 2021 Highlights ▪ Continued heavy investment in technology and innovation ▪ Accelerated pace of automation to 10 million manual tasks per quarter; exited 2021 with a run rate of 70 million tasks automated annually, up from 30 million at the end of 2020 ▪ Extended automation beyond robotic process
Slide 7: Additional Color on Cloudmed
7 Additional Color on Cloudmed1 ▪ Robust data-driven platform with deep revenue intelligence functionality to holistically address complex reimbursement challenges that providers face ▪ Deep dataset, fueled by 500 million patient encounters annually and 10x more data than R1, enables predictive anal
Slide 8: 2022 Priorities
8 2022 Priorities ▪ Ensure a high-quality outcome with three key goals in mind: ▪ Drive commercial success given our enhanced value proposition; unlock and accelerate growth potential presented by the modular channel ▪ Establish R1 as the technology and data platform leader in the industry ▪ Be reco
Slide 9: ESG Update
9 ESG Update ▪ Key highlights from 2021: ▪ Access to Healthcare: With the launch of Entri we combined our innovative technology with our financial advocacy to make healthcare simpler and remove barriers to high quality healthcare for patients ▪ Investments in Our People: ▪ Introduced new learning an
Slide 10: 4Q'21 Non-GAAP Results – Q/Q and Y/Y Comparison
10 4Q’21 Non-GAAP Results – Q/Q and Y/Y Comparison Note1: Adjusted cost of services, adjusted SG&A expense, and adjusted EBITDA are non-GAAP measures. A reconciliation of non-GAAP to GAAP measures is provided in the Appendix of this presentation. ($ in millions) 4Q'21 3Q'21 4Q'20 Key change driver(s
Slide 11: Full Year 2021 Non-GAAP Results - Y/Y Comparison
11 Full Year 2021 Non-GAAP Results - Y/Y Comparison Note1: Adjusted cost of services, adjusted SG&A expense, and adjusted EBITDA are non-GAAP measures. A reconciliation of non-GAAP to GAAP measures is provided in the Appendix of this presentation. ($ in millions) 2021 2020 Y/Y chg. Key change driver
Slide 12: Additional Commentary
12 Additional Commentary ▪ Generated $46 million in cash from operations in Q4 and $264.8 million in 2021 - Q4’21 cash balance declined sequentially due to $27 million used for share repurchases, $24.3 million for debt paydown, $18.3 million for capital expenditures and $10.7 million for deferred pa
Slide 13: Appendix
13JPM Healthcare Conference 2022 Appendix
Slide 14: Use of Non-GAAP Financial Measures
14 Use of Non-GAAP Financial Measures ▪ In order to provide a more comprehensive understanding of the information used by R1’s management team in financial and operational decision making, the Company supplements its GAAP consolidated financial statements with certain non-GAAP financial performance
Slide 15: Reconciliation of Non-GAAP Financial Measures
15 Reconciliation of Non-GAAP Financial Measures $ in millions Reconciliation of GAAP Net Income to Non-GAAP Adjusted EBITDA Reconciliation of GAAP SG&A to Non-GAAP SG&A Reconciliation of GAAP Cost of Services to Non-GAAP Cost of Services Note1: Other costs are comprised of strategic initiatives cos